NEW YORK (GenomeWeb) – Molecular diagnostics firm Admera Health announced today that it has received approval from the New York State Clinical Laboratory Evaluation Program for its 50-gene PGxOne Plus pharmacogenomics test. 

PGxOne Plus uses next-generation sequencing technology to interrogate genes with the aim of predicting how patients will respond to drug therapy in cardiology, psychiatry, pain management, and oncology, among other areas. Reports sent to clinicians include information on whether specific drugs should be avoided, alternative treatments, and dosage adjustments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.